跳至主要内容
临床试验/NCT07456930
NCT07456930尚未招募不适用

Real-World Assessment of Compl-AI in Predicting Early Discontinuation of Medication for Treatment of Opioid Use Disorder (MOUD) in Community and Specialty Treatment Programs

Tools4Patient2 个研究点 分布在 1 个国家目标入组 295 人开始时间: 2026年6月1日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
Tools4Patient
入组人数
295
试验地点
2
主要终点
Proportion of attended MOUD medication visits

研究概览

简要总结

The goal of this observational study is to learn whether the Compl-AI model can accurately predict who is likely to stop their medication for opioid use disorder (MOUD) early in adults receiving real-world treatment for opioid use disorder (OUD).

The main questions it aims to answer is:

can the model accurately predict early discontinuation of MOUD?

Because this study has no comparison groups, all participants receive their usual MOUD as part of routine care. Researchers will observe how participants engage with treatment and how well Compl-AI predicts their outcomes.

Participants will complete 4 visits, including a questionnaire about personal experiences during first visit and questions about their substance use and treatment history.

During the monthly study visits, the researchers will record in particular the attendance at MOUD medication visits, the medication adherence and any treatment discontinuation.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ability to understand and provide written informed consent.
  • Male and female participant 18 years of age at the time of consent.
  • Participant with OUD based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).
  • Eligible to receive MOUD per site standard of care or currently receiving MOUD initiated prior to study enrollment.

排除标准

  • Cognitive impairment that precludes the ability to provide written informed consent.
  • Already enrolled in another study/program.

结局指标

主要结局

Proportion of attended MOUD medication visits

时间窗: Observation period will be three (3) months.

Proportion of prescribed doses taken

时间窗: Observation period will be three (3) months.

次要结局

未报告次要终点

研究者

发起方
Tools4Patient
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验